Actually the out performed Pfizer in China, so more reps on the streets in China worked, but again, the competition was probably nothing like we see here, and thus the focus on smaller communities has been a success. BD
AstraZeneca had to crack which areas in China had the fastest growing incomes and people who could most afford the medication, as well as data to show “which hospital is hot, which doctor is hot,” Yin Xudong, head of AstraZeneca’s China operations, told the WSJ. But the company has faced some major challenges, including government corruption and poaching of its successful sales reps by other drugmakers.
http://blogs.wsj.com/health/2008/06/13/astrazeneca-finds-riches-in-chinas-provinces/
0 comments :
Post a Comment